Spartalizumab (Genetical Recombination)



Spartalizumab is a recombinant humanized monoclonal antibody composed of complementarity-determining regions derived from mouse anti-human PD-1 antibody, human framework regions and human IgG4 constant regions. In the H-chain, amino acid residue at position 225 is substituted by Pro, and Lys at the C-terminus is deleted. Spartalizumab is produced in Chinese hamster ovary cell. Spartalizumab is a glycoprotein (molecular weight: ca. 149,000) composed of 2 H-chains (γ4-chains) consisting of 443 amino acid residues each and 2 L-chains (κ-chains) consisting of 220 amino acid residues each.

[1935694-88-4]